| scholarly article | Q13442814 |
| P2093 | author name string | Raymond S Douglas | |
| P2860 | cites work | Psychosocial morbidity of Graves' orbitopathy. | Q51925700 |
| Efficacy and safety of radioiodine therapy for mild Graves ophthalmopathy depending on cigarette consumption: a 6‑month follow‑up. | Q54127045 | ||
| 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. | Q54429935 | ||
| New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor. | Q55024151 | ||
| Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial | Q79775301 | ||
| Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy | Q80293192 | ||
| Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy | Q82104621 | ||
| Cigarette smoking: number one enemy for Graves ophthalmopathy | Q88816874 | ||
| Acute thyroid eye disease (TED): principles of medical and surgical management | Q26827429 | ||
| Graves' Disease. | Q30243909 | ||
| Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases | Q33637524 | ||
| Teprotumumab for Thyroid-Associated Ophthalmopathy. | Q34556184 | ||
| Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. | Q35055076 | ||
| Randomized controlled trial of rituximab in patients with Graves' orbitopathy | Q35055124 | ||
| Assessing quality of life in Australian patients with Graves' ophthalmopathy | Q35591594 | ||
| The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy | Q36811289 | ||
| Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. | Q37417167 | ||
| Methotrexate for the treatment of thyroid eye disease | Q37616156 | ||
| Postoperative Changes in Strabismus, Ductions, Exophthalmometry, and Eyelid Retraction After Orbital Decompression for Thyroid Orbitopathy | Q39528775 | ||
| Thyroid-Related Orbital Decompression Surgery: A Multivariate Analysis of Risk Factors and Outcomes | Q40790395 | ||
| Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts | Q43845891 | ||
| Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. | Q44256446 | ||
| Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. | Q45096631 | ||
| Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway | Q46107628 | ||
| Effect of smoking on retrobulbar blood flow in thyroid eye disease | Q46835363 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | eye disease | Q3041498 |
| proptosis | Q12640503 | ||
| P304 | page(s) | 183-190 | |
| P577 | publication date | 2018-12-21 | |
| P1433 | published in | Eye | Q10278937 |
| P1476 | title | Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis | |
| P478 | volume | 33 |
| Q91858998 | Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review |
| Q90630299 | Current landscape in motoneuron regeneration and reconstruction for motor cranial nerve injuries |
| Q97421343 | Teprotumumab: a disease modifying treatment for graves' orbitopathy |
| Q91789199 | Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm |
| Q89843708 | Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy |
Search more.